European Commission approves contract with BioNTech-Pfizer alliance
European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
Today's contract with the BioNTech-Pfizer alliance builds upon the broad portfolio of vaccines to be produced in Europe, including the already signed a contracts with AstraZeneca, Sanofi-GSK and Janssen Pharmaceutica NV, and the concluded successful exploratory talks with CureVac and Moderna. This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective.
President of the European Commission, Ursula von der Leyen, said: "In the wake of Monday's promising announcement by BioNTech and Pfizer on the prospects for their vaccine, I'm very happy to announce today's agreement with the European company BioNTech and Pfizer to purchase 300 million doses of the vaccine. With this fourth contract we are now consolidating an extremely solid vaccine candidate portfolio, most of them in advanced trials phase. Once authorised, they will be quickly deployed and bring us closer to a sustainable solution of the pandemic."
Stella Kyriakides, Commissioner for Health and Food Safety, said: "A safe and effective vaccine is the only lasting exit strategy from the pandemic, and is at the centre of our European Vaccine Strategy. Today's agreement follows the encouraging first indications from the clinical trial results and is further evidence of our commitment to putting more Europe in the area of health. It is a very telling example of what the EU can achieve when working together, as a Union, and a case in point of what a future European Health Union will be able to deliver."
2026-10-25
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer and BioNTech achieve Health Canada authorization for their vaccine to com
-
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial
-
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial
-
FDA expert panel recommends EUA for Pfizer/BioNTech COVID-19 vaccine
-
Pfizer plans to ditch Perth sterile injectables manufacturing site by 2024
-
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
-
400 million doses! EU's first COVID-19 vaccine pre-purchase agreement to AZ
-
Semcorp's Hungarian Factory Ordered to Shut Down Over Pollution
-
BASF Plans IPO for Agricultural Solutions Business
-
LANXESS Expands Rubber Additives Production at Qingdao Plant
Recommend Reading
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
South Korea Moves Urgently to Control Petrochemical Feedstock Hoarding as Supply Chain Risk Escalates to the National Security Level
-
BASF Partners with Andritz for Carbon Capture Project in Aarhus
-
Dafeng Haijianuo’s RMB 246 Million Technical Revamp Project Takes Shape, with Multiple Production Lines for Vitamin K1, Folic Acid, and Others Under Construction
-
Evonik Achieves Successful Trial Production at Shanghai Polyamide Plant
-
Business Society’s Market Outlook for Epoxy Resins on August 25, 2026: Stable
-
Business Society’s Market Outlook for Lithium Carbonate on August 25, 2026: Volatile
-
“全球展会数据”功能上线公告 Announcement on the Launch of the “Global Exhibition Data” Function
-
Four Chinese Industrial Giants Compete for Wodgina Lithium Mine
-
Business Society’s Market Outlook for Maleic Anhydride on August 25, 2026: Volatile